Clinical decision making regarding leiomyomata: what we need in the next millenium.
Leiomyomata represent the most common gynecologic tumors and are responsible for over 200,000 hysterectomies per year. They are almost invariably benign and represent clonal expansion of individual myometrial cells. They can cause a variety of symptoms including menometrorrhagia, dysmenorrhea, pelvic pain, reproductive failure, and compression of adjacent pelvic viscera, or be totally asymptomatic. Leiomyomata are more common in African-American women and have a non-Mendelian inheritance pattern with up to a 50% recurrence rate after surgical removal. The therapeutic choices depend on the goals of therapy, with hysterectomy most often used for definitive treatment, and myomectomy when preservation of childbearing is desired. Intracavitary and submucous leiomyomata can be removed by hysteroscopic resection. Laparoscopic myomectomy is now technically possible but apparently with an increased risk of uterine rupture during pregnancy. Although gonadotropin-releasing hormone-agonist-induced hypogonadism can reduce the volume of leiomyomata, the severe side effects and prompt recurrences make them useful only for short-term goals such as reversing anemia or shrinking an intracavitary tumor prior to hysteroscopic resection. Nonextirpative approaches such as myolysis and uterine artery embolization are being evaluated, and may provide more options if they prove to be safe and efficacious in long-term follow-up. Ultimately, if the genetic basis for fibroid development and/or the molecular mechanism(s) of myometrial proliferation are understood, additional nonsurgical therapeutic interventions may be forthcoming. Current clinical needs are to a) determine an effective prevention strategy in genetically predisposed individuals; b) slow the growth of leiomyomata; c) identify the mechanisms of infertility; d) improve early detection; e) develop better surgical techniques; f) reduce recurrences after myomectomy; g) develop nonextirpative options; and h) evaluate their long-term results.
Haney
A F
AF
Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA. haney001@mc.duke.edu
D003661:Decision Support Techniques; D018450:Disease Progression; D004621:Embolization, Therapeutic; D020847:Estrogen Receptor Modulators / Q000627:therapeutic use; D005260:Female; D005544:Forecasting; D020022:Genetic Predisposition to Disease; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists / Q000037:antagonists & inhibitors; D006801:Humans; D007044:Hysterectomy / Q000009:adverse effects / Q000379:methods / Q000706:statistics & numerical data; D015907:Hysteroscopy / Q000009:adverse effects / Q000379:methods / Q000706:statistics & numerical data; D007889:Leiomyoma / Q000150:complications / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D020380:Needs Assessment; D009376:Neoplasms, Hormone-Dependent / Q000150:complications / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*; D018579:Patient Selection; D011247:Pregnancy; D011322:Primary Prevention; D012008:Recurrence; D014594:Uterine Neoplasms / Q000150:complications / Q000175:diagnosis* / Q000453:epidemiology / Q000628:therapy*
D020847:Estrogen Receptor Modulators; D007987:Gonadotropin-Releasing Hormone